Literature DB >> 15868652

Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study.

Umberto Gelatti1, Loredana Covolo, Michela Franceschini, Francesco Pirali, Alessandro Tagger, Maria Lisa Ribero, Paola Trevisi, Claudia Martelli, Giuseppe Nardi, Francesco Donato.   

Abstract

BACKGROUND/AIMS: The role of coffee in the development of hepatocellular carcinoma (HCC) is debated. The aim of this study was to investigate the role of coffee in HCC, taking the main risk factors into account.
METHODS: A hospital-based case-control study was conducted in an area of northern Italy. We recruited 250 HCC cases and 500 controls hospitalized for any reasons other than neoplasms, and liver and alcohol-related diseases. Subjects were interviewed on their lifetime history of coffee consumption using a standardized questionnaire.
RESULTS: Coffee consumption in the decade before the interview was associated with a decreasing risk of HCC with a clear dose-effect relation. With respect to non-drinking subjects, the odds ratios (ORs) were: 0.8, (95% CI 0.4-1.3) for 1-2 cups/day, 0.4 (95% CI 0.2-0.8) for 3-4 cups/day and 0.3 (95% CI 0.1-0.7) for 5 or more cups/day. The ORs for HCC decreased for drinking >2, compared to 0-2 cups/day of coffee, for an alcohol intake >80 g/day (OR from 5.7 to 3.3), for presence of hepatitis B virus infection (OR from 16.4 to 7.3) or hepatitis C virus infection (OR from 38.2 to 9.0).
CONCLUSIONS: Coffee drinking was inversely associated with HCC regardless of its aetiology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15868652     DOI: 10.1016/j.jhep.2004.11.039

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  30 in total

1.  Voluntary exercise together with oral caffeine markedly stimulates UVB light-induced apoptosis and decreases tissue fat in SKH-1 mice.

Authors:  Yao-Ping Lu; Bonnie Nolan; You-Rong Lou; Qing-Yun Peng; George C Wagner; Allan H Conney
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-30       Impact factor: 11.205

Review 2.  Chemopreventive strategies in hepatocellular carcinoma.

Authors:  Siddharth Singh; Preet Paul Singh; Lewis R Roberts; William Sanchez
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-08-13       Impact factor: 46.802

Review 3.  Interaction between hepatitis C virus and metabolic factors.

Authors:  Yasunori Kawaguchi; Toshihiko Mizuta
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

4.  Coffee: a panacea or snake oil for the liver?

Authors:  Radhika Kumari; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

Review 5.  Non-viral causes of hepatocellular carcinoma.

Authors:  Wojciech Blonski; David S Kotlyar; Kimberly A Forde
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

6.  Chemoprevention against hepatocellular carcinoma.

Authors:  Jun-Ichi Okano; Yuki Fujise; Ryo Abe; Ryu Imamoto; Yoshikazu Murawaki
Journal:  Clin J Gastroenterol       Date:  2011-06-04

7.  Insulin resistance and chronic liver disease.

Authors:  Takumi Kawaguchi; Eitaro Taniguchi; Minoru Itou; Masahiro Sakata; Shuji Sumie; Michio Sata
Journal:  World J Hepatol       Date:  2011-05-27

Review 8.  Coffee Drinking and Reduced Risk of Liver Cancer: Update on Epidemiological Findings and Potential Mechanisms.

Authors:  Manami Inoue; Shoichiro Tsugane
Journal:  Curr Nutr Rep       Date:  2019-09

Review 9.  Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations.

Authors:  Francesca Lodato; Giuseppe Mazzella; Davide Festi; Francesco Azzaroli; Antonio Colecchia; Enrico Roda
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

10.  Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.

Authors:  Charlotte E Edling; Federico Selvaggi; Ragheda Ghonaim; Tania Maffucci; Marco Falasca
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.